RxDoctor Payments Data

Christopher Larson

Ophthalmology · Sheboygan, WINPI 1750358693

Payments from drug & device makers

$1,066in general payments, 2019–2025

Across 31 payments — averaging $34.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$412
  • Medtronic$278
  • AbbVie$194
  • The Cameron-ehlen Group, Inc.$66
  • Bausch & Lomb Americas Inc.$65
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$32
  • plus $19 from 1 others

What the payments were for

  • Travel & lodging$19218%
  • Food & beverage$85580%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon6$412
Medtronic7$278
AbbVie(2 entities)10$194
The Cameron-ehlen Group, Inc.3$66
Bausch & Lomb Americas Inc.3$65
Bausch & Lomb, A Division Of Bausch Health US, LLC1$32
Carl Zeiss Meditec AG1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,066 in reported general payments places this provider in the 65th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$126,507
Medicare patients
351
Services billed
1,093

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine25$33,788
LumiganBimatoprost28$18,129
Prednisolone Acetate240$13,483
Latanoprost492$5,083
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat218$3,722
Ketorolac Tromethamine165$3,551
Ofloxacin159$2,712
Loteprednol Etabonate13$2,178
Dorzolamide Hcl62$1,548
Timolol Maleate118$1,208
Travoprost12$1,153
Atropine Sulfate25$984
Acetazolamide12$812
Brimonidine Tartrate91$697
MoxifloxacinMoxifloxacin Hcl24$634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$194$51,91753 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$32$2,17813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Sheboygan

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →